Holen Sie sich die Stockscreener-App
2.45
2.08%
0.05
Handel nachbörslich:
2.39
-0.06
-2.45%
Schlusskurs vom Vortag:
$2.40
Offen:
$2.35
24-Stunden-Volumen:
502.86K
Relative Volume:
2.46
Marktkapitalisierung:
$42.21M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-30.15M
KGV:
-0.6125
EPS:
-4
Netto-Cashflow:
$-21.66M
1W Leistung:
+20.10%
1M Leistung:
+26.94%
6M Leistung:
+105.88%
1J Leistung:
-30.40%
1-Tages-Spanne:
$2.30
$2.54
1-Wochen-Bereich:
$2.0151
$2.54
52-Wochen-Spanne:
$1.10
$6.01
Nrx Pharmaceuticals Inc Stock (NRXP) Company Profile
Firmenname
Nrx Pharmaceuticals Inc
Sektor
Branche
Telefon
484-254-6134
Adresse
1201 ORANGE STREET, WILMINGTON
Vergleichen Sie NRXP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NRXP
Nrx Pharmaceuticals Inc
|
2.45 | 35.14M | 0 | -30.15M | -21.66M | -4.00 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Nrx Pharmaceuticals Inc Stock (NRXP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-02 | Eingeleitet | BTIG Research | Buy |
Nrx Pharmaceuticals Inc Aktie (NRXP) Neueste Nachrichten
NRx Pharmaceuticals (NASDAQ: NRXP) Reports Q1 Results, Highlights Progress on Ketamine NDA and HOPE Clinic Rollup - The Globe and Mail
NRx Pharmaceuticals (NASDAQ: NRXP) Set to Report Q1 Earnings in Wake of HOPE’s Strategic Kadima Agreement - financial-news.co.uk
HOPE Therapeutics, Inc. a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Signing of Term Sheet for $7.8 Million Debt Financing to Fuel HOPE Clinic Acquisitions - The Malaysian Reserve
Earnings call transcript: NRx Pharmaceuticals targets profitability by end of 2025 in Q1 2025 - Investing.com Canada
NRx Pharmaceuticals Reports Q1 2025 Results and Strategic Progress - TipRanks
Transcript : NRx Pharmaceuticals, Inc., Q1 2025 Earnings Call, May 15, 2025 - marketscreener.com
NRX Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
HOPE Therapeutics secures $7.8 million for clinic acquisitions By Investing.com - Investing.com South Africa
$7.8 Million in New Financing for Clinic Acquisitions Supporting Purchase of Kadima Neuropsychiatry Institute as Treatment Model and Leading Investigative Site for Suicidal Depression and PTSD: NRXP - FinancialContent
HOPE Therapeutics, Inc. and NRx Pharmaceuticals (NASDAQ:NRXP) Announce Signing of Definitive Agreement to Purchase Kadima Neuropsychiatry Institute; Foundational Acquisition for the HOPE Network of Interventional Psychiatry Clinics - Kilgore News Herald
NRX Pharmaceuticals Reports First Quarter 2025 Financial Results And Provides Corporate Update - marketscreener.com
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports First Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Set to Report Q1 Earnings in Wake of HOPE's Strategic Kadima Agreement - Yahoo Finance
HOPE Therapeutics secures $7.8 million for clinic acquisitions - Investing.com Australia
NRX Pharmaceuticals Gets $7.8 Million Debt Financing From Universal Capital - marketscreener.com
HOPE Therapeutics Lands $7.8M Deal to Build National Mental Health Network with Ketamine Treatment Centers - Stock Titan
HOPE Therapeutics and NRx Pharmaceuticals to buy Kadima Institute - MSN
NRXP Expands with Acquisition of Kadima Neuropsychiatry Institut - GuruFocus
Plan Signed to Purchase Kadima Neuropsychiatry Institute as - openPR.com
Plan Signed to Purchase Kadima Neuropsychiatry Institute as Clinical Treatment Model and Leading Investigative Site Addressing Suicidal Depression and PTSD: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) | FinancialContent - FinancialContent
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary HOPE Therapeutics to Acquire Kadima Neuropsychiatry Institute - Yahoo Finance
NRx Pharma, Hope in pact to buy Kadima (NRXP:NASDAQ) - Seeking Alpha
HOPE Therapeutics to acquire Kadima Neuropsychiatry By Investing.com - Investing.com Nigeria
HOPE Therapeutics To Buy Kadima Neuropsychiatry Institute For Undisclosed Sum - Nasdaq
HOPE Therapeutics to acquire Kadima Neuropsychiatry - Investing.com
HOPE Therapeutics, Inc. and NRx Pharmaceuticals (NASDAQ:NRXP) Announce Signing of Definitive Agreement to Purchase Kadima Neuropsychiatry Institute; Foundational Acquisition for the HOPE Network of In - StreetInsider
NRx Pharmaceuticals (NASDAQ: NRXP) to Report Q1 2025 Results on May 15 - The Globe and Mail
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report First Quarter 2025 Financial Results on May 15, 2025 - BioSpace
Stocktwits Spotlight: NRx, CVS, ReShape Lead Weekly Jump In Health Care Stock Chatter - MSN
Plan Signed to Purchase Kadima Neuropsychiatry Institute as Clinical Treatment Model and Leading Investigative Site Addressing Suicidal Depression and PTSD: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - Barchart.com
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Investor Event at Mar-A-Lago Club on May 8, 2025 - PR Newswire
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Files Patent for Preservative-Free Ketamine Formulation - Yahoo Finance
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NR - GuruFocus
NRx Pharmaceuticals (NASDAQ: NRXP) Files Patent for Preservative-Free Ketamine Formulation - TipRanks
NRXP Seeks Patent for Innovative Depression Treatment | NRXP Sto - GuruFocus
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Patent Application for NRX-100, its Proprietary, Preservative Free Formulation of IV Ketamine - GuruFocus
NRx Pharmaceuticals seeks patent for preservative-free ketamine By Investing.com - Investing.com India
NRx Pharmaceuticals seeks patent for preservative-free ketamine - Investing.com
NRXP's Groundbreaking Ketamine Patent Could Secure 20-Year Market Exclusivity for Depression Treatment - Stock Titan
FDA Filing Fee Waiver for New Drug Application of NRX-100 for Suicidal Depression - Psychiatric Times
Potential Success With DBS: Reducing Stigma and Addressing Unmet Need - Psychiatric Times
$4.3 Million Waiver Exemption Granted by FDA on New Drug - openPR.com
$4.3 Million Waiver Exemption Granted by FDA on New Drug Application Fee for Promising Treatment Addressing Suicidal Depression and PTSD: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - Barchart.com
Wheat Sees Some Bargain Buying at Month End - The Globe and Mail
Neuroscience and Psychiatry: Mending the Schism - Psychiatric Times
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces FDA Award of F - GuruFocus
Finanzdaten der Nrx Pharmaceuticals Inc-Aktie (NRXP)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.54%
7.58%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):